Background {#Sec1}
==========

Warfarin is one of the most widely used coumarin anticoagulants in the treatment of atrial fibrillation, heart valve prosthesis, recurrent stroke, deep vein thrombosis and pulmonary embolism (Daly and King [@CR12]). However, its use is made difficult by the wide interindividual variation in dose required to achieve a therapeutic effect, the narrow therapeutic range, and the risk of serious bleeding (Landefeld and Beyth [@CR26]). Warfarin dose requirement, which varies 20-fold, is influenced by factors such as intake of vitamin K, ethnicity, illness, age, gender, concurrent medication, body mass index and genetic factors (Loebstein et al. [@CR33]; Takahashi and Echizen [@CR50]; Wadelius et al. [@CR58]).

Warfarin acts through interference with the recycling of vitamin K in the liver, which leads to secretion of inactive vitamin K-dependent proteins (Bell et al. [@CR3]; Dahlbäck [@CR11]). Figure [1](#Fig1){ref-type="fig"} shows the genes that are believed to be involved in the biotransformation of vitamin K, warfarin and the vitamin K-dependent clotting factors, here called the warfarin interactive pathways (Supplementary Table S1; for details see Wadelius and Pirmohamed [@CR69]). The main protein in the vitamin K epoxide reductase complex is encoded by *VKORC1* (Li et al. [@CR31]; Rost et al. [@CR43]). Common variation in human *VKORC1* is one of the most important genetic factors determining warfarin dose (D'Andrea et al. [@CR14]; Geisen et al. [@CR18]; Rieder et al. [@CR42]; Sconce et al. [@CR46]; Wadelius et al. [@CR57]; Veenstra et al. [@CR55]; Yuan et al. [@CR65]). Another putative subunit of the vitamin K epoxide reductase is the microsomal epoxide hydrolase 1, encoded by *EPHX1***,** which harbours a vitamin K-epoxide binding site (Cain et al. [@CR7]; Loebstein et al. [@CR32]; Morisseau and Hammock [@CR35]). Calumenin, encoded by *CALU*, binds to vitamin K epoxide reductase and inhibits the effect of warfarin (Wallin et al. [@CR61]; Wajih et al. [@CR59]). Fig. 1An overview of the interaction between warfarin and the 29 genes. This pathway illustrates genes thought to mediate the effects of warfarin. It also depicts a simplified representation of the biotransformation of warfarin and vitamin K

A high intake of the fat-soluble vitamin K~1~ can reverse the action of warfarin. Vitamin K~1~ is absorbed from the small intestine along with dietary fat, and subsequently cleared by the liver through an apolipoprotein E (APOE) receptor specific uptake (Berkner and Runge [@CR5]). The uptake of vitamin K~1~ into the liver varies between different *APOE* alleles and is in the order of \**E2* \< \**E3* \< *\*E4* (Saupe et al. [@CR45]; Kohlmeier et al. [@CR22]). It has also been suggested that the antioxidant enzyme nicotine adenine dinucleotide phosphate (NAD(P)H) dehydrogenase, encoded by NQO1, has the potential to reduce dietary vitamin K (Wallin and Hutson [@CR60]; Berkner and Runge [@CR5]).

Reduced vitamin K is the essential cofactor for the activation of vitamin K-dependent proteins by gamma-glutamyl carboxylase, encoded by *GGCX* (Wu et al. [@CR64]; Berkner [@CR4]). The main vitamin K-dependent proteins are clotting factors II, VII, IX and X, proteins C, S and Z, and the growth-arrest specific protein 6, encoded by *F2, F7, F9, F10, PROC, PROS1, PROZ* and *GAS6*, respectively (Berkner and Runge [@CR5]). A non-vitamin K-dependent clotting protein anti-thrombin III, encoded by *SERPINC1*, inhibits the vitamin K-dependent factors II, IX and X (Dahlbäck [@CR11]). Furthermore, the point mutation Arg506Gln (FV Leiden) in *F5* is a common cause of thromboembolism, and is therefore a known cause of warfarin treatment (Larsen et al. [@CR27]).

The molecular basis of warfarin pharmacokinetics has been extensively studied (Sanderson et al. [@CR44]). Warfarin is administered as a racemate that consists of R- and S-enantiomers, the S-form being 3--5 times more active than the R-form (Rettie et al. [@CR40]). Warfarin is rapidly absorbed from the stomach and the upper gastrointestinal tract (Palareti and Legnani [@CR38]), and in the circulating blood it is highly bound to albumin and alpha 1-acid glycoproteins, encoded by *ORM1* and *ORM2* (Otagiri et al. [@CR37]). Once warfarin has entered the liver, S-warfarin is metabolised by cytochrome *P*~450~ 2C9 (CYP2C9) (Rettie et al. [@CR40]; Kaminsky and Zhang [@CR21]). Patients with *CYP2C9* variant alleles *\*2* and *\*3* alleles (<http://www.imm.ki.se/CYPalleles/>) require lower mean daily warfarin doses than extensive metabolisers homozygous for the *\*1* wild type allele do, and may have a greater risk of bleeding, especially during the induction of therapy (Sanderson et al. [@CR44]). The enzymes CYP2C8, CYP2C18, CYP2C19 may also play a role in the metabolism of S-warfarin (Rettie et al. [@CR40]; Kaminsky and Zhang [@CR21]). R-warfarin is mainly metabolised by CYP1A2 and CYP3A4 (Rettie et al. [@CR40]; Zhang et al. [@CR66]; Kaminsky and Zhang [@CR21]). In addition, CYP1A1, CYP2C8, CYP2C18, CYP2C19 and CYP3A5 may be involved in the metabolism of R-warfarin (Rettie et al. [@CR40]; Zhang et al. [@CR66]; Kaminsky and Zhang [@CR21]; Huang et al. [@CR20]). Cytochrome *P*~450~ enzymes are induced by the nuclear hormone receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR), which are encoded by *NR1I2* and *NR1I3* (Lehmann et al. [@CR29]; Chen et al. [@CR9]). Based on an inhibition assay, there is some evidence that transport of warfarin out of the liver and into the bile may be mediated by P-glycoprotein, which is encoded by *ABCB1* (*MDR1*) (Sussman et al. [@CR49]). P-glycoprotein can be induced by the nuclear hormone receptor PXR (Geick et al. [@CR17]).

We and others have shown that common variants in the *VKORC1* and *CYP2C9* genes together with a limited subset of environmental determinants account for around 50--60% of the variance in warfarin dose requirement (Sconce et al. [@CR46]; Wadelius et al. [@CR57]; Veenstra et al. [@CR55]; Aquilante et al. [@CR1]; Lee et al. [@CR28]; Takahashi et al. [@CR52]; Vecsler et al. [@CR54]). Here, we fine map the *VKORC1* and the *CYP2C* gene cluster loci on chromosomes 16 and 10, respectively, and assess common variation in 27 other genes in the warfarin interactive pathways for association with dose requirements. Finally, we evaluate the potential contribution of all positively associated genes to a warfarin dose model, which includes age, bodyweight, concomitant medication and indication for treatment.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Two hundred and one Caucasian patients were recruited at Uppsala University Hospital in 2000; 194 patients of Swedish origin, four of other European descent and three from the Middle East (Wadelius et al. [@CR58]). Their mean age was 66.7 years (range 28--88 years), and 1/3 of them were women. They had been treated with warfarin (Waran^®^, Nycomed AB, Stockholm, Sweden) for a minimum of 2 months (range 2.4 months--26 years, median 2 years), and their prothrombin time international normalised ratio (PT INR) had been stabilised. At the six following visits, five weekly warfarin doses and five corresponding PT INR were registered. Individual warfarin dose requirement ranged from 4.5 to 77.25 mg/week. Information about age, gender, bodyweight (missing in seven patients), treatment indication and duration, other diseases and concurrent medication was taken from the patients' medical records, and the details have been presented previously (Wadelius et al. [@CR58], [@CR57]. Patients were stratified into two groups depending on indication for treatment: patients with heart valve prosthesis (*n* = 49), where a higher target INR usually is recommended, and patients treated for other indications such as atrial fibrillation (*n* = 113), thromboembolic disease (*n* = 9), cardiomyopathy (*n* = 8) and transischemic attack (*n* = 5). Concurrent medications were registered, and drugs were classified as interacting if they had moderate or major interactions with warfarin according to the database MICROMEDEX^®^ Healthcare Series (<http://www.micromedex.com/>) (May 2002). The patients had a total of 107 concurrent medications known to influence warfarin. They were divided into three groups: individuals with drugs that lower the effect of warfarin by inducing its metabolism (*n* = 4), those with medications that potentiate the effect of warfarin (*n* = 74) and patients without any known interactions (*n* = 123). The study was approved by the local Ethics Committee.

Genotyping {#Sec4}
----------

DNA was extracted from whole blood using QIAamp^®^ DNA Blood Mini Kit (QIAGEN Ltd., Crawley, UK). Within the 29 candidate genes including 5 kb up- and downstream flanking regions, we selected available single nucleotide polymorphisms (SNPs), preferably with minor allele frequency (MAF) \> 5% and spread out as evenly as possible every 2--5 kb. The first set of SNPs was selected from dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) prior to the HapMap (<http://www.hapmap.org/index.html.en>), which was later used for gap filling in regions where the tested SNPs failed or were monomorphic in our population. In addition, we mined functional polymorphisms from the literature. In the process circa 900 SNPs were tested. SNP assays were designed with the SpectroDESIGNER™ software.

The *GGCX* microsatellite marker in intron 6 was analysed as described earlier (Chen et al. [@CR8]). SNP typing was performed with the Homogeneous Mass Extend assay (Sequenom, Hamburg, Germany). Polymerase chain reaction (PCR) amplification was performed in 5-μL reactions using 3.5 ng DNA and 150 nM of each forward and reverse primer, 200 μM deoxynucleotide triphosphates (dNTPs), 1 ×  PCR buffer, and 0.04 U Titanium^®^ polymerase (BD BioSciences, Clontech, CA, USA). Cycling conditions were 94°C for 15 min, followed by 45 cycles of 94°C for 20 s, 56°C for 30 s and 72°C for 1 min, and then 72°C for 3 min. Primer extension, sample clean up and MALDI-TOF Mass Spectrometry analysis were performed as described elsewhere (Whittaker et al. [@CR63]). Primer sequences are available on request.

Genotyping was carried out at a multiplex level of four SNPs per well and data quality was assessed by duplicate DNA (*n* = 4). SNPs with more than one discrepant call or showing self-priming in the negative control (water) were removed. Finally, we removed non-polymorphic SNPs, SNPs with call rate below 70%, and markers that departed from Hardy Weinberg equilibrium (*P* \< 0.001).

Statistical analysis {#Sec5}
--------------------

Univariate and multiple analyses of predictor's impact on the square root of warfarin dose were calculated using linear regression models as implemented by SAS and SPLUS software. To account for partial dependence among tests of SNPs in linkage disequilibrium (LD), we applied both the Bonferroni correction for multiple testing based on calculating the effective number of independent tests (*M*~eff~) and a Permutation procedure (Cheverud [@CR10]; Li [@CR30]; Nyholt [@CR36]). LD was visualised using the HaploView software (Gabriel et al. [@CR16]). The QTPHASE component of UNPHASED software was used to estimate haplotype frequencies, calculate means and variances of warfarin dose associated with each haplotype, and statistically test for differences among the haplotype means (Dudbridge [@CR15]). Pairwise LD was quantified by the standard *r*^2^ measure (Pritchard and Przeworski [@CR39]). The proportion of explained variance (coefficient of determination) was measured by *R*^2^.

Results and discussion {#Sec6}
======================

Association of warfarin dose with individual markers {#Sec7}
----------------------------------------------------

We selected 29 candidate genes in the warfarin interactive pathways (Fig. [1](#Fig1){ref-type="fig"} and Supplementary Table S1) and tested them for ∼800 SNPs that comprehensively captured common variation based on measures of LD (*r*^2^ ≥ 0.8). In addition, we tested almost 100 functional polymorphisms including several published variants reported to be associated with warfarin dose, however, most of the tested functional SNPs were later excluded due to being monomorphic or having very low MAF. We identified 348 SNPs (Supplementary Table S2) that passed quality control and had a MAF of at least 4% in our sample of 201 warfarin patients. Note that results for *VKORC1, GGCX* and *CYP2C9* are based on the reanalysis of SNPs presented by Wadelius et al. ([@CR57]) together with additional SNPs typed in this study. Univariate regression analysis showed that 32 polymorphisms in or flanking the genes *VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, EPHX1, CALU, GGCX, ORM1* and *ORM2* were nominally associated with warfarin dose requirement (Table [1](#Tab1){ref-type="table"}). In addition, the two polymorphisms that discriminate between *APOE*\**E2, \*E3* and \**E4* were significantly associated with dose when assessed together (Table [1](#Tab1){ref-type="table"}). In determining correction for multiple testing, we compared the Permutation procedure with the Bonferroni correction based on the effective number of independent traits (Bonferroni *M*~eff~) and found that the two methods yielded very similar *P*-value cut-points (Cheverud [@CR10]; Li [@CR30]; Nyholt [@CR36]). In this study, we present the number of effective tests within each gene obtained by the Bonferroni *M*~eff~ method. The number of independent effective tests within each gene or gene cluster varied from 2 to 50, implying gene-wise corrected cut-points of *P* \< 0.025 to \< 0.001. Assuming that the genes are independent of each other, the sum of effective tests over all genes was 285. This makes *P* \< 0.05/285, which equals *P* \< 0.000175, the cut-off level for experiment-wise significance. Using this cut-point, *VKORC1*, *CYP2C9*, *CYP2C18* and *CYP2C19*, were associated with dose after experiment-wise correction for multiple testing, while *PROC* and *APOE* were significant only after within-gene correction (Table [1](#Tab1){ref-type="table"}). Ten *F2* SNPs, 41 *F5* SNPs, 11 *F7* SNPs, 11 *F9* SNPs, 15 *F10* 15 SNPs, 13 *PROZ* SNPs, 11 *PROS1* SNPs, four *GAS6* SNPs, nine *SERPINC1* SNPs, nine *NQO1* SNPs, three *CYP1A1* SNPs, three *CYP1A2* SNPs, two *CYP3A4* SNPs, seven *CYP3A5* SNPs, 12 *CYP2C8* SNPs, 20 *NR1I2* SNPs, nine *NR1I3* SNPs and 38 *ABCB1* SNPs passed the study criteria, but none of them were significantly associated with warfarin dose (Supplementary Table S2). Table 1Genes with significant association with warfarin dose, based on univariate regression of square root of doseGeneSNPMAF*n*Univariate *R*^2^*P*-Value*r*^2^ with best SNP*VKORC1*rs99232310.3911810.3171.91 × 10^−15^\*\*--rs23596120.3892000.2902.30 × 10^−15^\*\*0.968rs99344380.3831690.2923.59 × 10^−13^\*\*1.000rs72940.3841880.2084.14 × 10^−10^\*\*0.385rs48894900.4461990.1603.821 × 10^−8^\*\*0.461rs48895370.3721990.1423.158 × 10^−7^\*\*0.209rs48895990.3661940.1243.270 × 10^−6^\*\*0.305rs80469780.2141970.0470.009060.173rs116426030.0931920.0270.023040.070rs116424660.1031950.0250.026230.080rs71943470.3431970.0320.040690.153*CYP2C9*rs1057910 (\*3)0.0582010.1412.784 × 10^−7^\*\*--rs93321080.0642010.1412.784 × 10^−7^\*\*0.890rs93254730.0551890.1473.753 × 10^−7^\*\*0.908rs10579110.0671910.1454.218 × 10^−7^\*\*0.890rs93322140.0591980.1394.654 × 10^−7^\*\*0.878rs49176390.1731970.1184.944 × 10^−6^\*\*0.276rs28609050.2141930.0720.00080\*0.224*CYP2C19*rs38146370.0591950.1060.00002\*\*0.838^a^rs17882687(\*15)0.081830.0440.00417\*0.395^a^*CYP2C18*rs78961330.0561930.0740.00013\*\*0.869^a^*PROC*rs20699190.3721820.0900.00022\*--rs17998090.4331880.0780.00055\*0.777rs20699010.4411770.0720.00147\*0.785rs20699100.3871780.0460.016780.414*APOE*rs429358 + rs7412^b^0.2512010.0510.00570\*--*EPHX1*rs46534360.2661960.0480.00848--*CALU*rs116530.3661970.0470.00944--rs10060230.3312000.0330.037890.865rs23070400.3362000.0330.038110.867rs3390540.4611950.0320.044870.612*GGCX*rs127141450.4081980.0340.03320--*ORM1-2*rs16873900.0621490.0260.04964--The SNPs are listed with the lowest *P*-value first. The LD (*r*^2^) between the SNP with the lowest *P*-value and others in the gene or gene cluster is shown. *n* is the number of successfully genotyped individuals^a^Linkage disequilibrium with *CYP2C9\*3* (rs10579103)^b^Note that the two *APOE* SNPs are not significant individually, only when assessed as *E2* + *E4* vs. *E3*\*The test is significant, based on correction for the effective number of tests in each gene or gene cluster\*\*Corresponds to experiment-wise significance, based on ∼285 independent effective tests (*P* \< 1.75 × 10^−4^)

Association of warfarin dose with haplotypes {#Sec8}
--------------------------------------------

Haplotype analysis showed 12 genes to be nominally associated with warfarin dose (Table [2](#Tab2){ref-type="table"}), namely *VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, GGCX, PROZ, F9, NR1I2* and *ORM1*-*ORM2*. Compared with the univariate single-marker analysis, four additional genes, *F7*, *PROZ*, *F9* and *NR1I2* were associated at *P* \< 0.05. The haplotypes that exhibited the lowest *P*-values in each candidate gene are listed in Table [2](#Tab2){ref-type="table"}. *VKORC1*, *CYP2C9*, *CYP2C18* and *CYP2C19* showed experiment-wise significance for haplotype analysis, as they did for single markers. Likewise, *PROC* was significant at a gene-wise level. Table 2Two or three marker haplotype giving the lowest *P*-value in each candidate geneGeneHaplotype*P*-valueSmaller?^a^*VKORC1*rs9934438-rs99232315.76 × 10^−15^\*\*No*CYP2C9*rs9332214^b^-rs9332222^c^-rs22980374.86 × 10^−9^\*\***Yes***CYP2C18*rs1926711-rs7919273^b^-rs105096753.47 × 10^−7^\*\***Yes***CYP2C19*rs2860840-rs3814637^b^2.08 × 10^−6^\*\***Yes***PROC*rs2069919-rs2069921-rs9737601.36 × 10^−3^\*No*F7*rs3093229-rs30932332.42 × 10^−2^**Yes***GGCX*Microsatellite^d^-rs762684-rs67386451.78 × 10^−2^**Yes***PROZ*rs2273971-rs30247113.57 × 10^−2^**Yes***F9*rs401597-rs3929593.83 × 10^−2^**Yes***NR1I2*rs2461818-rs76436453.93 × 10^−2^**Yes***ORM1-2*rs1687390-rs37620554.93 × 10^−2^No*P*-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose. Genes not shown did not produce a nominally significant (*P* \< 0.05) haplotype result^a^Yes indicates that the haplotype *P*-value is smaller than the *P*-value for the best single marker in the same gene^b^Strongly associated with *CYP2C9\*3*^c^Strongly associated with *CYP2C9\*2*^d^*GGCX* microsatellite described by Chen at al. ([@CR8])\*Gene-wise significance based on correcting for the effective number of tests in each gene. The other *P*-values are of nominal significance (*P* \< 0.05)\*\*Experiment-wise significance (*P* \< 1.75 × 10^−4^)

Fine mapping of the *VKORC1* and *CYP2C* regions {#Sec9}
------------------------------------------------

*VKORC1* on chromosome 16 was the single gene most strongly associated with warfarin dose (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). We previously described five SNPs in *VKORC1* in an extended region of high LD spanning over 300 kb in the Swedish sample (Fig. [2](#Fig2){ref-type="fig"}). In this sample, three of the SNPs (rs2359612, rs9934438, rs9923231) were perfectly correlated with pairwise LD *r*^2^-values of ∼1.0 and accounted for ∼30% of the warfarin dose variance (*R*^2^) (Wadelius et al. [@CR57]). An important goal of this study was to fine map *VKORC1*. Each of ten additional SNPs in the *VKORC1* region (Fig. [2](#Fig2){ref-type="fig"}a) was tested to determine if it added significantly more dose variance to a multiple regression model that included one of the three linked SNPs (rs2359612), *CYP2C9\*2* and *\*3*, and non-genetic predictors of warfarin dose (Supplementary Table S3). Our results demonstrated that: (a) each of the three linked SNPs predicted more dose variance (∼30%) than any other genotyped *VKORC1* SNP, and (b) none of the other ten flanking SNPs predicted additional dose variance (Fig. [2](#Fig2){ref-type="fig"}). In accordance, no *VKORC1* haplotype yielded association *P*-values more significant than the three linked SNPs (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The molecular mechanism by which the three linked SNPs influence warfarin response has not been resolved. Due to the high LD between the three SNPs in our population, it is not possible to discern which of them that is responsible for the effect on warfarin. None of the studied SNPs are coding, and thus do not alter protein structure. Instead the effect may be mediated by altering the amount of drug target in the liver as postulated by studies showing that *VKORC1* 5′ SNPs are correlated with liver levels of mRNA (Rieder et al. [@CR42]) and with activity in a reporter assay (Yuan et al. [@CR65]); however, a third study failed to show this (Bodin et al. [@CR6]). Fig. 2Fine mapping of the *VKORC1* locus. **a** Location of SNP markers (MAF ≥ 5%) in a ∼550 kb region surrounding *VKORC1* which is coded on the reverse strand and is located at the right end of the LD block. Previously reported SNPs are shown in *red* (11). **b** The univariate *r*^2^ (*pink, left axis*) and *P*-value (*blue, right axis*) are shown for each SNP. The black line near 10^−3^ on the *right* axis indicates the *P*-value that is necessary to achieve significance after within-gene Bonferroni correction. **c** HaploView analysis with pair-wise *r*^2^ illustrating the extent of LD in the region. The *red dotted triangle* indicates the LD block defined with data of the HapMap project (CEU panel)

The *CYP2C* gene cluster on chromosome 10 was the second most strongly associated region after *VKORC1* (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). This region of high LD includes *CYP2C9, CYP2C8*, *CYP2C18* and *CYP2C19* (Supplementary Fig. S1). Several *CYP2C* SNPs were associated with warfarin dose, even after correction for multiple testing. The functional polymorphism in *CYP2C9\*3* (rs1057910, I359L), which severely impairs the capacity to hydroxylate S-warfarin (Haining et al. [@CR19]), was the most strongly associated SNP in this region (Table [1](#Tab1){ref-type="table"}). The functional *CYP2C9\*2* polymorphism (rs1799853, R144C) confers only a moderate reduction in the metabolism of S-warfarin (Rettie et al. [@CR41]), and was not significant in univariate analysis. In fine mapping of the *CYP2C* region, we successfully genotyped 53 additional SNPs: 17 in *CYP2C9*, ten in *CYP2C19*, 14 in *CYP2C18* and 12 in *CYP2C8*. In univariate analysis, significant association was observed for nine SNPs apart from *\*3* including the *CYP2C19* 5′ upstream rs3814637, the *\*15* allele and the intronic *CYP2C18* rs7896133 (Table [1](#Tab1){ref-type="table"}). The *CYP2C19\*2A* allele, which leads to an inactive CYP2C19 enzyme, was in agreement with earlier studies not associated (Takahashi et al. [@CR51]; Scordo et al. [@CR47]). To test whether any of the other *CYP2C* SNPs accounted for additional dose variance, apart from the 2.4 and 10.9% explained by *CYP2C9\*2* and *\*3*, two multiple regression models were used (Table [3](#Tab3){ref-type="table"}). Both models contained *VKORC1* (rs2359612) and significant non-genetic predictors of warfarin dose, whereas one contained *CYP2C9\*2* but not *\*3* and vice versa. Each one of the 55 *CYP2C* SNPs was evaluated against the two multiple regression models. This showed that except for the *CYP2C9* SNP rs4917639, all significant results were fully explained by LD with either *CYP2C9\*2or\*3*. In contrast, *CYP2C9* SNP rs4917639 gave a significant *P*-value in both the *\*2* model (*P* \< 1.33 × 10^−9^) *and* the *\*3* model (*P* \< 3.56 × 10^−3^). The minor allele of rs4917639 was in perfect LD (*r*^2^ = 1) with a composite minor allele formed by aggregating *CYP2C9\*2* and *\*3* into a single allele, although *\*2* and *\*3* are rarely carried on the same haplotype (McGinnis et al. [@CR34]). These data suggest that the rs4917639 mutation occurred first, and that rs1799853 and rs1057910, which are diagnostic for *\*2* and *\*3*, arose independently on the same parent allele. The strong association between rs4917639 and *\*2/\*3* could perhaps be due to positive selection, if rs4917639 lessened the deleterious effect of impaired CYP2C9 metabolism caused by *\*2* and *\*3*. This and related possibilities merit further investigation given the unusual pattern of LD between rs4917639 and *\*2/\*3.*Table 3Significant (*P* \< 0.05) regression results for SNPs in the CYPC2 gene clusterGeneSNP*R*^2^ with \*2 model*P*-Value*R*^2^ with \*3 model*P*-Value*CYP2C8*rs115720800.0010.5020.0170.005*CYP2C9*rs93321080.1091.57 × 10^−10^0.0000.999*CYP2C9*rs1057910 (***\*3***)0.1091.57 × 10^−10^----*CYP2C9*rs10579110.1142.97 × 10^−10^0.0000.999*CYP2C9*rs93254730.1125.45 × 10^−10^0.0000.999*CYP2C9*rs49176390.1001.33 × 10^−9^0.0253.56 × 10^−3^*CYP2C9*rs93322140.0981.50 × 10^−9^0.0000.999*CYP2C9*rs28609050.0481.86 × 10^−4^0.0090.153*CYP2C9*rs49176360.0040.2130.0263.63 × 10^−3^*CYP2C9*rs46079980.0040.2520.0262.85 × 10^−3^*CYP2C9*rs1799853 (***\*2***)----0.0244.00 × 10^−3^*CYP2C9*rs19349660.0000.9990.0158.72 × 10^−3^*CYP2C9*rs93322220.0000.9990.0253.86 × 10^−3^*CYP2C18*rs78961330.0635.17 × 10^−7^0.0000.999*CYP2C18*rs29017830.0200.0290.0040.471*CYP2C19*rs38146370.0983.76 × 10^−9^0.0000.896***CYP2C19***rs178826870.0475.19 × 10^−5^0.0000.828Additional dose variance (*R*^2^) explained by each SNP and the corresponding *P*-value is shown for two multiple regression models of warfarin dose. Both models contain *VKORC1* SNP rs2359612 and non-genetic predictors identified by Wadelius et al. ([@CR57]). *CYP2C9\*2* is included in the first alternative regression model and *CYP2C9\*3* is included in the second model. A non-significant *P*-value for the *\*2* model but highly significant result for the *\*3* model implies that *\*2* fully accounts for the tested SNP's contribution to dose variance (and vice versa). Thus, *\*2* or *\*3* fully account for each tested SNP apart from rs4917639SNPs giving non-significant (*P* \> 0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163, rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628, rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891, rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419, rs4417205, rs1853205)

Other genes tentatively associated with warfarin dose {#Sec10}
-----------------------------------------------------

Of the 13 *PROC* SNPs included in the analysis, four were significantly associated with dose: rs1799809 A \> G and rs2069901 T \> C in the 5′ regulatory region of *PROC*, rs2069910 C \> T in intron 2 and rs2069919 G \> A in intron 3 (Table [1](#Tab1){ref-type="table"}). The two promoter polymorphisms and the intron 3 polymorphism reached gene-wise significance and explained 7--9% of the variance in warfarin dose; *P* = 0.0002--0.0015. Haplotypes of *PROC* were also significantly associated with dose, but did not increase the statistical confidence since the lowest *P*-value was 0.00136 (Table [2](#Tab2){ref-type="table"}). Unlike most other vitamin K-dependent factors, protein C acts as a natural anticoagulant by inactivating factors Va and VIIIa, but all its activities are not yet fully understood (Dahlbäck [@CR11]). Intriguingly, it has previously been shown that protein C activity is negatively correlated with PT INR, not only in patients treated with oral anticoagulants, but also in healthy subjects and in medical patients without oral anticoagulants (Watala et al. [@CR62]). Two other studies have found that homozygosity for the G allele of the *PROC* promoter polymorphism rs1799809 is associated with slightly reduced concentrations and activities of protein C (Spek et al. [@CR68]; Aiach et al. [@CR67]). In our study, carriers of rs1799809 G/G, had lower dose requirements than others (*P* = 0.00055). If rs1799809 G/G individuals have a reduced pre-treatment protein C activity (Spek et al. [@CR68]; Aiach et al. [@CR67]), which according to Watala et al. ([@CR62]) is associated with higher PT INR, then this might explain their low-warfarin dose requirements. However, this theory needs to be tested in a larger population. A Japanese group previously failed to find an association between warfarin dose and the rare synonymous coding *PROC* SNP rs5935 (Shikata et al. [@CR48]), which was not polymorphic in our sample.

We analysed the two *APOE* SNPs that define the widely used *\*E2, \*E3* and *\*E4* allelic system. Patients who carried the common allele *\*E4* or the rarer *\*E2* required higher warfarin doses than those with *\*E3*; *P* = 0.0057. This result was significant after within-gene correction for multiple testing (Table [1](#Tab1){ref-type="table"}). We previously reported that CYP2C9 extensive metabolisers who were homozygous for *APOE\*E4* required higher warfarin doses than other extensive metabolisers; *P* = 0.0008 (Kohnke et al. [@CR24]). This is supported by a Dutch study that found slightly higher maintenance doses of the anticoagulant phenprocoumon in *APOE\*E4* homozygous individuals (Visser et al. [@CR56]). Surprisingly, the same study found that *APOE\*E4* carriers required lower maintenance doses of acenocoumarol. No homozygous *\*E4* individuals were found among Italian patients, and the association between warfarin dose requirements and *APOE* genotype was not seen (Kohnke et al. [@CR23]). These discrepant results indicate that the association between anticoagulant dose and *APOE*, if any, is weak. In addition, they point out that a future warfarin dose prediction model may not be applicable to phenprocoumon and acenocoumaron.

Nine other genes were nominally associated with warfarin dose, but did not pass correction for multiple testing: *GGCX, F7, PROZ, F9, EPHX1, CALU, NR1I2*, *ORM1* and *ORM2* (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). It has been shown that warfarin dose tends to increase with the number of repeats of a microsatellite in intron 6 of *GGCX* (Shikata et al. [@CR48]; Chen et al. [@CR8]). A haplotype including the microsatellite was more significant than the intron 2 SNP rs12714145 reported by Chen et al. ([@CR8]), however, both failed to reach gene-wise significance (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The SNP rs5896 causing a threonine to methionine change at position 165 in the prothrombin gene (*F2*), which was reported to confer warfarin sensitivity (D'Ambrosio et al. [@CR13]; Shikata et al. [@CR48]), did not replicate in our study; *P* = 0.2923. *F7*, *F10* and *PROZ* are positioned in close proximity, and *F7* promoter polymorphisms are claimed to have an effect on warfarin sensitivity (D'Ambrosio et al. [@CR13]; Shikata et al. [@CR48]; Aquilante et al. [@CR1]). A haplotype located 2 kb upstream of *F7* was tentatively associated with dose, and so was a *PROZ* haplotype comprising SNPs 5′ upstream of the gene and in the first intron (Table [2](#Tab2){ref-type="table"}). On the other hand, the coding *F7* SNP rs6046 (R413Q, formerly R353Q) that may lead to decreased plasma levels of factor VII (Arbini et al. [@CR2]), and the synonymous SNP rs5960 in the exon 7 of *F10* did not affect warfarin dosing (Shikata et al. [@CR48]). The rare variant in *F9* (A-10V/T) that causes a disproportional reduction in factor IX activity in warfarin-treated patients (Kristensen [@CR25]; van der Heijden et al. [@CR53]) was not found in our study population, although a haplotype covering this region showed nominal association to dose (Table [2](#Tab2){ref-type="table"}). A recent study has shown an association between high doses of warfarin in CYP2C9 extensive metabolisers carrying the non-synonymous *EPHX1* SNP rs1051740 which results in a tyrosine to histidine substitution at residue 113 (Loebstein et al. [@CR32]). We failed to replicate this finding, although rs4653436 located 5′ upstream was nominally associated with dose (Table [1](#Tab1){ref-type="table"}). A coding SNP in *CALU* (R4Q), that is suspected to increase warfarin dose requirement in *CYP2C9* and *VKORC1* wild type patients (Vecsler et al. [@CR54]), was not significantly associated with dose in our study. However, the 3′ UTR *CALU* SNP rs11653, the non-synonymous rs2307040 and the two intronic rs339054 and rs1006023 gave borderline significant *P*-values (Table [1](#Tab1){ref-type="table"}). The nominal association between warfarin dose requirements and a haplotype of *NR1I2* has to our knowledge not previously been shown (Table [2](#Tab2){ref-type="table"}). Warfarin's association with rs3762055 located between *ORM1* and *ORM2*, and with a haplotype covering this region are also novel findings (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The weaker associations observed for these tentatively associated genes require testing and validation in an independent and larger data set. Finally, it is worth mentioning that the prothrombotic *F5* Leiden variant (rs6025) had no effect on warfarin dose requirement in our study (*P* = 0.4925).

Multiple modelling {#Sec11}
------------------

To explore the potential of a warfarin dose prediction model, we combined the genes with the largest impact on warfarin dose (*VKORC1*, *CYP2C9* and *PROC*) with patient characteristics (age, bodyweight, interaction with other drugs and indication for treatment) in a multiple regression model. This model explained 62% of the variance in dose. We then considered all nominally associated genes, *VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, APOE, EPHX1, CALU, GGCX* and *ORM1-2* in a model, which explained 76% of the interindividual variance in warfarin dose. Variables with individual *P*-values above 0.2 and a low-explanatory value (*R*^2^) were subsequently removed from the model in a stepwise manner. We finally reached a model containing *VKORC1*, *CYP2C9\*2* and *\*3, PROC*, *EPHX1, GGCX, ORM1-2*, age, bodyweight and drug interactions which explained 73% of the variance in warfarin dose (Table [4](#Tab4){ref-type="table"}). However, this speculative model requires validation in a large independent sample of warfarin patients. Table 4Multiple regression model that explains 73% of the variance in warfarin dosePredictorSNP*P*-ValueUnivariate *R*^2^*VKORC1*rs9923231\<0.00010.317*CYP2C9*rs1799853 (*\*2*) + rs1057910 (*\*3*)\<0.00010.159Age0.00290.092*PROC*rs20699190.04160.090Bodyweight0.00750.057*EPHX1*rs46534360.10160.048Interaction0.08780.036*GGCX*rs127141450.02600.034*ORM1*rs16873900.05710.026Univariate *R*^2^-values are included for comparison

Conclusion {#Sec12}
==========

*VKORC1*, *CYP2C9, CYP2C19, CYP2C18, PROC* and *APOE* were all significantly associated with warfarin dose after correction for multiple testing. Three linked *VKORC1* SNPs and the *CYP2C9* allele *\*3* were the strongest genetic factors determining warfarin dose requirements. We fine mapped the *VKORC1* and *CYP2C* regions in search of polymorphisms that might explain additional dose variance in our Swedish study population. However, none of the *VKORC1* SNPs or haplotypes accounted for more dose variance than the three linked SNPs. Likewise, no *CYP2C* polymorphism contributed more to dose variance than *CYP2C9\*2* or *\*3.* Apart from *VKORC1* and *CYP2C9*, the most significant finding was the association of SNPs in *PROC* that reached gene-wise significance. Although factors II, VII and X have the strongest influence, it has been shown that protein C, the product of the *PROC* gene, has an effect on one of the outcome parameters of the current study, i.e. the prothrombin time (Watala et al. [@CR62]). If genetic variation in *PROC* influences the prothrombin time, which in turn determines the required warfarin dose, it is not improbable that genetic variation in *PROC* plays a role for warfarin dose. Furthermore, as previously reported, CYP2C9 extensive metabolisers who were homozygous for *APOE\*E4* required higher warfarin doses than others (Kohnke et al. [@CR24]). Replication in a larger patient cohort will ascertain whether *PROC* and *APOE* are true determinants of warfarin dosing.

With this systematic warfarin study, we can explain 62% of the variance in warfarin dose in Swedish patients by using a multiple regression model of *VKORC1*, *CYP2C9\*2*/*\*3, PROC* and non-genetic factors. The addition of *EPHX1, GGCX* and *ORM1-2*, to the model predicts an extra ∼10% of the variance. However, this model requires further validation in independent and larger samples, and will be tested in the WARG (<http://www.druggene.org/>) cohort of 1,500 Swedish warfarin treated patients. Even so, this future model will only be applicable for patients of European ancestry, and similar studies need to be performed in other ethnic groups. When all common alleles contributing to warfarin response have been identified in the major ethnic groups, a comprehensive dose model that is applicable regardless of ethnicity can be developed. Dosing models may subsequently be translated into clinical guidelines for warfarin prescription, and could have a major impact on the safety and efficacy of warfarin.
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ABCB1

:   ATP-binding cassette transporter B1 gene, P-glycoprotein gene or MDR1

APOE

:   Apolipoprotein E

CALU

:   Calumenin gene

CAR

:   Constitutive androstane receptor

CYP1A1

:   Cytochrome *P*~450~ 1A1

CYP1A2

:   Cytochrome *P*~450~ 1A2

CYP2A6

:   Cytochrome *P*~450~ 2A6

CYP2C18

:   Cytochrome *P*~450~ 2C18

CYP2C19

:   Cytochrome *P*~450~ 2C19

CYP2C8

:   Cytochrome *P*~450~ 2C8

CYP2C9

:   Cytochrome *P*~450~ 2C9

CYP3A4

:   Cytochrome *P*~450~ 3A4

CYP3A5

:   Cytochrome *P*~450~ 3A5

EPHX1

:   Epoxide hydrolase 1, microsomal gene

F2

:   Coagulation factor II gene or prothrombin gene

F5

:   Coagulation factor V gene

F7

:   Coagulation factor VII gene

F9

:   Coagulation factor IX gene

F10

:   Coagulation factor X gene

FII

:   Coagulation factor II or prothrombin

FIIa

:   Coagulation factor II activated or thrombin

FIX

:   Coagulation factor IX

FIXa

:   Coagulation factor IX activated

FV

:   Coagulation factor V

FVII

:   Coagulation factor VII

FVIIa

:   Coagulation factor VII activated

FX

:   Coagulation factor X

FXa

:   Coagulation factor X activated

GAS6

:   Growth-arrest specific 6

GGCX

:   Gamma-glutamyl carboxylase gene

MDR1

:   Multidrug resistance gene 1, P-glycoprotein gene or ABCB1

NQO1

:   NAD(P)H dehydrogenase, quinone 1 gene

NR1I2

:   Pregnane X receptor gene

NR1I3

:   Constitutive androstane receptor gene

ORM1

:   Orosomucoid 1 gene or Alpha-1-acid glycoprotein 1 gene

ORM2

:   Orosomucoid 2 gene or Alpha-1-acid glycoprotein 2 gene

PCR

:   Polymerase chain reaction

PROC

:   Protein C gene

PROS1

:   Protein S gene

PROZ

:   Protein Z gene

PT INR

:   Prothrombin time international normalised ratio

PXR

:   Pregnane X receptor

SERPINC1

:   Anti-thrombin III gene

siRNA

:   Small interfering ribonucleic acid

SNP

:   Single nucleotide polymorphism

UTR

:   Untranslated region

VKORC1

:   Vitamin K epoxide reductase complex subunit 1 gene
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